

Annual Report 2021



Trustees' Report

For the year ended 30 June 2021

What we do and why it matters

The British Society for Immunology is the award winning (Best Overall Association 2020, The Association Awards) and leading UK membership organisation working with scientists and clinicians from academia and industry to forward immunology research and application around the world. Our friendly, accessible community consists of over 4,000 immunologists, giving us a powerful voice to advocate on immunological science and health for the benefit of society.

The Society supports its members, students and the wider public to learn more about immunology through disseminating research and providing resources, activities and grants to aid education in this field.

Immunological science underpins many aspects of human and animal health and disease, from communicable disease and vaccination to the management and treatment of many chronic conditions. Through enhancing our knowledge of how the immune system functions for the public benefit, the British Society for Immunology can play a key role in advancing Society's ability to prevent and treat disease.

Our mission

The British Society for Immunology's mission is to promote excellence in immunological research, scholarship and clinical practice in order to improve human and animal health.

We accomplish this by:

- Working with our members to support current and future generations of immunologists.
- Sharing our passion for immunology through meetings, publications and the media.
- Building up an understanding of our work by engaging with the public and those working in the research and health environments.
- Working with partners in pursuit of our mission, building on common interests

The Trustees confirm they have referred to the Charity Commission's guidance on public benefit when reviewing the Society's aims and objectives, planning future activities and setting the annual operating plan.

Our strategic objectives


1. Grow membership
2. Promote the internationalism of Immunology
3. Develop an integrated publications strategy
4. Extend our relevance and impact through our policy and external affairs activities
5. Diversify our income

1 Membership

Our members are at the heart of everything we do. The United Kingdom is a world leader in immunological research, and immunology underpins many aspects of recent advances in our knowledge of human and animal health and disease. As the largest professional immunology society in Europe and third largest in the world, we are a friendly, accessible community for immunologists from all disciplines, which supports diversity and works across different sectors and national borders. We work with members from across the spectrum of the discipline, from basic science through to clinical application, and from different sectors, to support current and future generations of immunologists.

Membership of the British Society for Immunology brings many benefits. These include discounts to our meetings and to our exceptional BSI Congress, access to a diverse range of grants, bursaries and prizes, free access to our journals and much more. The Society provides tailored support for our community through our highly valued Regional and Affinity Groups, but we are also there to represent immunology to the wider world. Members value our strong voice to speak out with influence and impact on behalf of immunology in policy, public engagement and the media.

At the end of June 2021, we had over 4,000 members who join us from all walks of immunology. From students up to senior levels, they contribute to our work through many different routes, including speaking at our conferences, helping with our public engagement activities and advising on our policy work – our grateful thanks go to our whole immunology community.



The BSI's first ever virtual conference, 'Connecting immunology in the time of COVID-19', took place on 1-2 December 2020. We welcomed over 780 attendees and connected with people from 31 countries. We were honoured to welcome Sir Patrick Vallance, the UK Government's Chief Scientific Advisor, to join the 'Immunology and COVID-19' plenary session which also featured a presentation from Professor Paul Moss and Dr John Grainger on behalf of the UK Coronavirus Immunology Consortium (UK-CIC). Speaking on the day that the Pfizer-BioNTech COVID-19 vaccine was approved for UK use, Sir Patrick reflected on his role of Chief Scientific Advisor during the pandemic and the huge advances that we have made in our understanding of the disease's biology, treatments, and vaccines.

We hope to reunite in person in November 2021 for the return of the BSI Congress in the beautiful city of Edinburgh.

Regional and Affinity Groups

The BSI's Regional and Affinity Groups are a key part of the BSI community and carry out much of the core activity of bringing our membership together. The scientific discussions and networking that take place at these meetings are invaluable for the continued development of immunology. The strengths of our 17 Regional Groups are to bring together immunologists within a local community, boosting local research networks. The 12 Affinity Groups have all been created to focus meetings and discussions on specific areas of immunology and they continue to evolve as immunology expands its reach and knowledge.

Our programme of events was disrupted by COVID-19; however, many of the groups switched their events online and were able to keep members engaged and up to date with almost 3,500 people attending. It is planned to reintroduce physical events when restrictions allow.

Keeping members informed

The BSI works hard to ensure good communication channels with our members to keep them informed about our activities and about developments in immunology in the wider world. This has been a particularly important part of our activities this year with the COVID-19 pandemic. The popularity of our website continues to grow with over 4.22 million page views this year and 2.38 million unique users. This is an increase of 59% and 92% respectively compared with last year's figures. The BiteSized Immunology section continues to be popular along with our new Coronavirus information hub, which collects the BSI's activities on COVID-19 with useful resources for our members and the wider public. Our infographics on COVID vaccines are the most viewed pages on the site.

4.22m
page views

2.38m
unique users

BSI email communications to members and additional subscribers have become a mainstay for keeping the immunology community informed and connected, with audience numbers growing considerably over the course of the year. Our flagship membership magazine *Immunology News* is published quarterly and continues to be a popular way of engaging with our members. The magazine includes feature articles from leading immunologists, an education and careers section and more information on our activities. As it contains many articles likely to be of interest to a broad audience range, it is an important part of our work to increase exposure of the BSI to the immunology community and beyond.

Our social media channels continue to grow in importance as a way of engaging with our membership and the wider world at a more immediate level, to interact with our supporters and spread the word about our work and the wonders of immunology. This year has been a success story for our social media channels with touchpoints such as BSI virtual conference, our **Vaccine Engagement Starts at Home** campaign and our coronavirus work being especially influential in driving our engagement figures. We have also run several campaigns to highlight the diversity of our membership, including supporting Women in Science Day and #BlackInImmunology week. Twitter has seen an increase in followers of 31% compared with last year, while our LinkedIn audience has grown by 44%. We've also seen a significant increase in our Instagram following and engagement, particularly amongst non-immunologist followers driven by our interactive COVID-19 vaccines Q&As. Our posts on Twitter were seen almost 4 million times. Across all channels, our social media posts were seen over 3.6 million times, with LinkedIn at 580k and Facebook at almost 700k.

31%
More Twitter
followers

44%
More LinkedIn
followers

3.6 million
Social media post
views

Supporting members throughout their career

The BSI is a hub of expertise to support our members in forging strong careers in the many sectors in which immunologists are employed. It is essential that our members feel supported at all stages of their careers, from undergraduate through to retirement, and beyond. One of our core responsibilities is to offer careers and educational support to current and future generations of immunologists. We do this through ongoing initiatives, such as our grants schemes, our education website BiteSized Immunology and our highly rated mentoring scheme.

BiteSized Immunology

BiteSized Immunology is our highly popular online educational resource which provides a comprehensive overview of the immune system, delivered in short self-contained articles that highlight major 'take home' messages. The content is designed for use by bioscience undergraduates, A-level students and anyone with an interest in the subject. This year, we have continued to review current content and commission new articles to ensure we keep up to date with the immunology field.

Each month, BiteSized Immunology receives an average of 192,502 page views, up 70% from last year.

Teaching recognition

Supporting higher education immunology teachers is important to ensure that the next generation are inspired to follow a career in immunology. The BSI runs several initiatives to support this sector of membership. Our Immunology Teaching Excellence Award recognises outstanding immunology teachers at higher education institutes in the UK. Now in its fourth year, we were delighted to present the award to Dr Nigel Francis, a Honorary Associate Professor at the University of Swansea Medical School. The judges felt that Nigel was a dedicated and passionate immunologist who demonstrated commitment, innovation and creativity in his teaching to bring the subject to life to students at all levels. It was clear to the judges that Nigel's teaching skill is valued by students and colleagues alike.

Mentoring scheme

The success of our mentoring scheme has continued apace. This key part of our strategic plan aims to support professional development among the immunology community, bringing together senior scientists with early career researchers to assist the next generation of immunologists with career development and progression.

Our 2020 intake of 8 mentor-mentee pairs all valued the scheme and finished well with positive feedback all round. For 2021, the popularity of the scheme more than quadrupled to 50 mentors and mentees taking part (which does indicate the need for this type of activity within the community). Due to the pandemic, training was switched online but this has increased accessibility of the scheme. Initial feedback indicates the scheme is working well.

Winter School

An important part of our mission is to support future generations of immunologists. This year, we adapted our Winter School event to a virtual setting. This one-day online event gave immunology students at a Master's degree level the opportunity to hear from top immunologists. With over 260 people registered, the delegates heard from 6 leading immunologists giving tailored talks on the latest updates in their area along with the opportunity to ask questions. There was also a career development session and a mental wellbeing session. Feedback on the event was very positive.

Career Development Webinars

Providing access to credible, useful and informative careers resources is a key aim of the BSI. This year, we continued our success in providing webinars on different aspects of career development, providing all members, no matter where they are based, with access to our career's resources.

We completed our initial webinar series which took a wide-ranging look at the different types of skills that BSI members need to be successful in their careers. This included how to manage a lab successfully and how to write a grant application.

This was followed up with a six-part webinar series for BSI members on 'Careers in immunology'. This looked at the different career routes that individuals can take after studying immunology, ranging from publishing, public engagement and lab technician. This has been a particularly important offering to our early career members to allow them to find out more about the opportunities open to them. Feedback has been hugely positive.

Grants to support members

A significant proportion of BSI funds is distributed to its members through our grant schemes to support their research, help them to build their transferable skills and to participate in outreach projects. Although some of our grant schemes were disrupted by the COVID-19 pandemic meaning some activities – such as travel to international conferences – could no longer go ahead, the BSI remains committed to supporting its members through these schemes in the future when circumstances allow.

Travel Awards and Lab Placement Grants

All travel award schemes were paused by the society in line with government guidance. We plan to re-open the awards when the situation allows and physical conferences resume.

Communicating Immunology Grants

We supported 8 projects through this scheme with the aim of stimulating interest, discussion and understanding of immunology among a public audience. Projects ranged from creating animated videos to explain how COVID-19 vaccines work to illustrations about how the immune system fights off pathogens.

Equality, Diversity & Inclusion Activity Grants

This new grant scheme aimed to support BSI members by funding activities and events that promote diversity and inclusion across the immunology community and the wider biomedical sciences. In this pilot year of the scheme, we funded 7 grants. Projects ranged from funding a workshop to support researcher mental health to a project to decolonise and diversify some immunology units on the university curriculum.

2 Promoting the internationalism of immunology

As immunological research develops, the international networks that underpin our cutting-edge, cross-disciplinary discoveries become increasingly important. The Society has always been ambitious in terms of our international reach, something we know our members value highly. We understand that it's now more important than ever for us to have a prominent voice on the international stage, speaking up for immunology and the UK research community.

We actively engage with our international counterparts on a regular basis through membership of the European Federation of Immunological Societies (EFIS) and the International Union of Immunological Societies (IUIS).

European Federation of Immunological Societies (EFIS)

The BSI is leading the EFIS taskforce on vaccines. The taskforce aims to work together to promote evidence-based information on vaccines across Europe, looking at how we can influence the policy environment. The taskforce will also be a forum to share information and promote best practice between societies. The taskforce has made good progress this year, publishing a policy document in February on COVID-19 vaccines. This was used by EFIS members to send to their governments to provide evidenced-based information on COVID-19 vaccines. Plans are now underway on the public engagement front too to provide translated information resources for the public on how vaccines work and commonly asked questions around COVID-19 vaccines.

The BSI is taking part in an initiative entitled yEFIS (young EFIS) to create a network of early career researchers across Europe. The group have several plans including hosting sessions at the upcoming European Congress of Immunology.

In June, the UK hosted the world's first Global Vaccine Confidence Summit. Bringing together public and private sector experts from around the world, the summit aimed to drive forward collective action to build global vaccine confidence and increase vaccine uptake in the fight against COVID-19. We ran a campaign calling on the UK Government to make improving global vaccine confidence a specific legacy project of the 2021 G7 conference. As well as writing to the Prime Minister, our members also joined us on social media to raise their voices and amplify this message.

3 Develop an integrated publications strategy

The BSI's original ethos still lies at the heart of our Society – to disseminate research with the aim of promoting and advancing immunology to foster future innovation. The BSI is proud to achieve this aim through the publication of our two well established official journals, *Immunology* and *Clinical & Experimental Immunology*. Working with the publisher Wiley, our journals provide a significant proportion of the Society's income.

It's been a busy year for journals as we work hard to ensure they maintain their competitive edge considering the current changes in the publishing industry. 2020 saw the impact factor for *Immunology* climb from 5 to 7, its highest ever.

Immunology

The Journal of cells, molecules, systems and technologies

British Society for
immunology

7.397

Impact Factor

859,600
downloads
(2020: 650,157)

636
submissions

Clinical & Experimental Immunology
The Journal of Translational Immunology



Clinical & Experimental Immunology had another good year with an increase in submissions and 43% more downloads. It reached its highest impact factor of 4.330 driven by successful review series.

4.330
Impact Factor

969,360
downloads
(2020: 680,171)

43%
More downloads



Our new open access journal, *Immunotherapy Advances*, was launched in November. The number of submissions has been encouraging hitting our target with 26 articles accepted in its first eight months.

37 articles
submitted

25,974
downloads

4 Extend our relevance and impact through our policy and external affairs activities

The BSI's policy and public affairs work have strengthened significantly over the past year to raise our profile and take forward engagements with policymakers to bring about meaningful change for immunology. Achievements last year include:

- Through our Parliamentary Questions programme, we had 61 written questions answered, submitted by MPs from all the main political parties.
- Met with nine MPs and members of the House of Lords, including Shadow Health and Social Care Secretary, Jon Ashworth MP, Vaccines Minister Nadhim Zahawi MP, and Lord Bethell, Parliamentary Under Secretary of State at the Department of Health and Social Care. Also met with many other individuals playing a significant role in the pandemic response including Deputy Chief Medical Officer, Jonathan Van Tam and Susan Hopkins, Strategic Response Director for COVID-19 in Public Health England.

- Responded to 5 consultations on a wide range of topics including COVID-19 pandemic, research funding and diversity and inclusion in science.
- Gave oral evidence to two Select Committee inquiries on vaccine passports.
- Worked with the Mayor of London's office to aware awareness of the importance of COVID vaccines
- We became an official supporter of the All Party Parliamentary Group on Diversity and Inclusion in STEM and sponsored their report on 'Equality in the STEM workforce'
- Participated in stakeholder network meetings with the Royal Society of Biology (including Parliamentary Links Day and Voice of the Future), Association of Medical Research Charities, Campaign for Science and Engineering and the Royal Society.

Focus on Coronavirus and COVID-19

The Coronavirus outbreak has affected our lives in countless ways. From our jobs and research to our wellbeing and the way we connect to our peers, the immunology community has had to rapidly adapt to this new world. At the same time as adjusting to the pandemic ourselves we pivoted rapidly to support our members and wider communities with respect to the science of the pandemic.




Research focus

We continued our webinar series called 'Connect on Coronavirus' which brings expert opinion and emerging science from internationally renowned researchers to our membership and beyond. These webinars have been highly popular with up to 1,500 people viewing live and many hundreds more viewing the recordings afterwards. They are free and open to all and have been lauded as a vital resource for the community to remain up to date on COVID-19 research.

Policy focus

The BSI worked hard to ensure that the Government recognises that proper understanding of immunology is critical to the country's response. Most of this work has been carried out through our COVID-19 expert taskforce, led by BSI Trustee Professor Deborah Dunn-Walters, which brings together 18 of UK's leading immunologists to provide expert advice to input to the BSI's policy work on COVID-19.

The key achievement of the taskforce has been to publish three expert reports throughout the year "Long-term immunological health consequences of COVID-19", "The ageing immune system and COVID-19" and "Immunity and COVID-19". These were widely circulated and made significant impact in increasing knowledge about the immune system and COVID-19 amongst policymakers. The last of these reports was cited by Lord Patel, Chair of the House of Lords Science and Technology Committee, in the House of Lords, which led to a meeting with Lord Bethell, the Parliamentary Under Secretary of State at the Department of Health and Social Care, responsible for life sciences, research and COVID-19 long term health impacts



In January, we issued a statement around the decision to extend the dosing schedules for the COVID vaccines. This had a significant effect as at the time there were few expert voices speaking out on the issue. The statement was referenced by Chief Medical Officer, Chris Whitty, in a live Number 10 press briefing and extensively quoted in the media. From this, we were also invited to provide an expert briefing to the Labour Shadow Cabinet on the issue and to meet with Jonathan Van Tam, Deputy Chief Medical Officer.

Throughout the year, we have engaged extensively with Parliament around COVID-19, providing briefings for individual MPs, giving evidence to the APPG on Coronavirus, providing a background briefing for the APPG on Blood Cancer on immunosuppression and COVID vaccines to name but a few.


When the COVID vaccines were first rolled out, we produced some highly popular Q&A sheets for MPs to help them answer potential questions that their constituents might send them about COVID vaccines. We received lots of positive feedback on how helpful these were and they also led to several face-to-face meetings with MPs.

More recently, several other BSI members have given evidence on behalf of the BSI to different select committee around the immunology underlying the assumptions around vaccine passports. Several of our members have also spoken in policy events including to the Parliamentary and Scientific Committee.


Public engagement

Engaging with the public on immunology is one of the key aims of the BSI and we've been busy working to achieve this, both through running public engagement initiatives ourselves and through providing support to our members to build their engagement skills. Ensuring that the public has access to reliable, evidence-based immunology information has become more important with the coronavirus pandemic and the need for us all to understand the science to make informed choices about our health. Key activities included:

- Developing our highly regarded "Guide to Vaccinations for COVID-19", a guide for the public to explain how vaccines work and provide answers to commonly asked questions. We update this every month to make sure the information contained is accurate. This has received great praise from public and experts alike – the Director for Public Health for Hertfordshire called it "by far the most up to date and accurate guide". TV doctor Chris Van Tulleken said "This guide is a phenomenal piece of work and will answer almost any question about COVID vaccines". Our guide is now linked signposted from government sites including Public Health Scotland.



- Throughout the year, we have run Instagram Q&As to allow members of the public to send in questions about COVID-19 vaccines that are then answered by an expert immunologist. This has proved very popular and we have received lots of engagement from the public.
- We have developed numerous infographics to help explain how vaccines work. This includes infographics on types of COVID-19 vaccine, vaccine ingredients, why have the vaccines been developed so fast, natural versus vaccine induced immunity, and the immune response after COVID vaccination. These are now some of the most accessed pages on our website and are regularly used by BSI members and the public to help explain to others the science behind vaccination.




- We had a particular focus on vaccines, fertility and pregnancy and worked with BSI member Viki Male to produce a video to answer common questions on this topic.
- We worked with the Royal Society of Biology to produce explainer videos aimed at younger adults on why it was important for them to get the COVID vaccines.
- We worked with the University of Edinburgh to produce several animations explaining different aspects of how immune memory works after COVID infection and why you need two doses of the COVID vaccines.
- We have worked with many organisations to help find expert speakers to engage with their communities and answer questions about vaccines. This includes a broad range from working with the Cabinet Office, different local councils, Science Museum etc.
- We worked with the Mayor of London's office to produce videos featuring our members from diverse communities answering common questions around vaccination. These were put out via social media channels and on community hubs for use.
- We collaborated with the London Borough of Bexley and Bexley Voluntary Services Council to develop a course on how to have productive conversations about COVID-19 vaccines (more details below).
- Took part in online events such as Swansea Science Festival and Dr Jenner's House Discovery at Home to increase public understanding around vaccines.
- In November, we took part in I'm a Scientist: an online, student-led STEM enrichment activity, connecting students with scientists through real-time text-based chats. The BSI part-sponsored the 'Health Zone' with a focus on vaccine immunology. Fifteen BSI members took part and had online conversations with school students to answer their questions about vaccines and what it's like to have a career as a scientist.
- We submitted an activity to the British Science Week activity pack for primary school students. We adapted the 'herd immunity Jenga' activity for their 'Innovating for the future' theme. Early evaluation stats are that the pack has been downloaded a total of 52,470 times.

- We are working with a number of individuals and organisations to translate some of our vaccine resources to make them more accessible to other communities. This includes a number of Yiddish translations, undertaken in collaboration with the Contemporary Hasidic Yiddish research team at University College London, funded by the Arts and Humanities Research Council. Other translations are in the pipeline and will be released soon.
- We collaborated with Nature Reviews and the Francis Crick Institute to put on an online event about COVID-19. With high profile speakers including Peter Hotez and Teresa Lambe, this event attracted well over 1,500 registrations and was well received.
- We produced several infographics and accompanying blog to explain how COVID testing works, including information on PCR and antibody tests.



Testing for COVID-19

What happens when you get infected with the SARS-CoV-2 virus?



How does testing work?

	PCR testing	Antibody testing
The test uses...	Swabs from the nose and throat	Blood sample
The samples are used...	In a lab test to identify the presence of SARS-CoV-2 genetic material	To test if there are any antibodies present that match and bind to the viral protein
The test tells us...	✓ who currently has an infection	✓ who has previously had an infection
The test does NOT tell us...	✗ about someone's immune response	✗ whether someone is necessarily protected from future infection
When is the test used?	During an active infection when the virus is in the body even if the person has no symptoms	From a week to several months after infection
How accurate is it?	PCR is an established technique providing a very sensitive test with high accuracy. False negative results are possible if the swab doesn't pick up enough virus.	Optimizing, evaluating and validating these tests is important. There are two approved lab tests being used in the UK but neither are 100% accurate.




BSI is proud to be
Immunology
www.immunology.org

A huge thank you to all the BSI members who have assisted us with these activities.

Engaging with members on COVID-19 vaccines

Our members are all expert immunologists but they are also mothers, fathers, sons, daughters, trusted friends and members of their communities and that puts them in an excellent position of trust within their networks to have conversations about vaccines to improve public understanding. People can sometimes lack the confidence to have these conversations so the BSI ran a series of events and activities aimed at helping our members to build their confidence and engagement skills to have these conversations. We:

- Developed a database of BSI members who wanted to take part in COVID vaccine engagement activities. This has been hugely helpful to us in enabling us to find suitable volunteers for different opportunities.
- Ran two webinars for members “Effective ways of engaging with the public” and “Discovering your path to effective public engagement” to help provide members with training on how to have effective conversations about vaccines. Both webinars had extensive opportunities to ask questions to the speakers.
- Ran our ‘Vaccine Engagement Starts At Home’ campaign to provide helpful tips and advice to members on how to have conversations about vaccines with friends and family
- Developed a series of case studies of different activities that BSI members are carrying out around COVID vaccines to engage and inspire others to get involved.



Media highlights

Through our media work, we aim to promote evidence-based and accurate coverage of immunology in the news and ensure that journalists have access to relevant experts who can provide knowledgeable responses. We do this through providing expert comment to breaking news stories, working with programme researchers to shape TV or radio broadcasts and through providing background briefings.

This year, our media work has again been dominated by two topics which have received very high levels of coverage: vaccination and COVID-19. The BSI has been a strong expert voice on both topics, ensuring that the expert voice of immunologists features prominently in this fast-moving, complex and high-profile story. We have worked closely with the Science Media Centre throughout, including running a number of high profile media briefing for national journalists.

Our coverage has included all major national news outlets such as BBC, ITV News, Sky News, The Times, The Guardian, Daily Mail, Daily Telegraph, Daily Mirror and The Sun. International coverage has included Reuters, CNN, Associated Press, Washington Post amongst many others.

- 40 BSI press release/response statements
- 220 articles in UK national press
- 1,000+ article in worldwide press

Partnerships

Working in partnership is core to how the British Society for Immunology operates. Immunology touches on numerous disease areas and other research disciplines and is a central pillar of the life sciences and medical ecosystem. As such, it's critical to our work that we engage with like-minded organisations to take forward our mission and collaborate on areas of common interest and perspective. Growing our partnership portfolio across all our activities will allow us to achieve our strategic goals and bring increased benefits for our members and the discipline.

Key partnerships this year include:

- Connect Immune Research, working with JDRF, MS Society and Versus Arthritis and others on autoimmune research.
- National Cancer Research Institute, working to move the cancer immunotherapy field forward
- Supporting the UK Coronavirus Immunology Consortium, a UKRI/NIHR funded initiative to bring together 20 of the UK's leading immunology research institute to increase our knowledge of the immune system and COVID-19 to improve public health
- London Borough of Bexley and Bexley Voluntary Service Council to provide a training course for community champions and health and social care workers on how to have productive conversations about COVID-19 vaccines
- Mayor of London's office to produce social media assets answering common questions on COVID-19 vaccines.
- International Day of Immunology, working with Nature Research and the Francis Crick Institute to hold a scientific symposium and public event on COVID-19 vaccines
- Royal Society of Biology, ensuring that the discipline of biology has a strong voice on the national stage
- Association of Clinical Pathologists to run training days for clinical immunology trainees and immunology biomedical and clinical scientists preparing to sit the Royal College of Pathologists Fellowship examinations.

- Science Media Centre, providing evidence-based expert response to immunology news stories of national importance
- Campaign for Science and Engineering, providing a strong voice to Government of the collective views on the science and research sector
- Association of Medical Research Charities, representing the health and medical research charity sector on a wider stage.

Connect Immune Research

Connect Immune Research is a collaboration between several charities that support autoimmune research – JDRF, the MS Society, Versus Arthritis and the British Society for Immunology. Traditionally, autoimmune conditions have been researched and treated in disease-specific silos but underlying common immunological mechanisms have indicated the benefit of a joined-up research approach. Our partnership is designed to bring about a critical change in the way autoimmune conditions are researched, bringing together the different disease areas to facilitate a joined-up approach to grow funding and research infrastructure and speed up clinical discovery.

This year, we have added several new organisations to the coalition including Alopecia UK and Psoriasis and Psoriatic Arthritis Alliance. We have also undertaken a major new stream of work collaborating with the Lorna and Yuti Chernajovsky Biomedical Research Foundation. Our aim is to work together to provide significant funding aimed at quickly developing proof of principle for potential new treatments for multiple immune-mediated inflammatory conditions by targeting pathways common in autoimmunity. An initial scoping day was held with the immunology community in May and plans are underway to launch the grant scheme in 2021-22.

London Borough of Bexley and Bexley Voluntary Service Council

A partnership between the BSI, London Borough of Bexley and Bexley Voluntary Services Council delivered a pilot programme to train champions within local community leaders and health/social care workers to have effective conversations with their networks and peers, answering questions and concerns about COVID-19 vaccines. The training was co-designed with 2 different groups (community leaders and health/social care workers), and consisted of 1-hour online sessions each week for 5 weeks. The sessions were led by immunologists skilled at engagement, with appearances from local faith leaders and healthcare professionals.

The content focused on building understanding of vaccines, as well as developing skills on listening to and answering questions and concerns. Sessions were user-led, addressing topics raised by participants and their communities.

Both groups had positive experiences. 100% of community leaders strongly agreed or agreed that they felt better informed, more knowledgeable, and confident to have effective conversations as well as reporting that they increased the number of people they talked to about COVID-19 vaccines. 92% of healthcare workers strongly agreed or agreed that they felt better informed and more knowledgeable about COVID-19 vaccines, while 85% strongly agreed or agreed that they felt more confident about having effective conversations. 70% of healthcare workers agreed or strongly agreed that they had increased the number of people they talked to about COVID-19 vaccines. Working in partnership was key to success of the project in reaching people on the front line who hold social capital and thus increased the impact of the project.

UK Coronavirus Immunology Consortium

The UK Coronavirus Immunology Consortium (UK-CIC) is a nationally targeted effort to understand the immunology of SARS-CoV-2 and COVID-19. This project has received £6.5 million of funding over 12 months from UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), and involves leading immunologists from 20 centres of excellence around the UK.



The British Society for Immunology was a supporting partner of UK-CIC throughout its 12 months of funding. BSI President, Professor Arne Akbar, acted as chair of the UK-CIC Scientific Advisory Board, which delivered independent oversight and input to its strategic priorities. The BSI also provided secretarial services to this board, including organising the agenda, arranging presentations from UK-CIC researchers, and providing minutes after each meeting.

The BSI also implemented the Patient and Public Involvement (PPI) programme, sourcing a panel of representatives that offered unique insights and perspectives on UK-CIC research. The BSI organised regular meetings with the PPI panel, with similar administrative support to the Scientific Advisory Board meetings. We have also worked with the PPI panel on several public engagement activities including research summaries, webinars, videos, and on a formal manuscript on PPI involvement in UK-CIC research.

The BSI ran communications for UK-CIC to engage with researchers, the public, and policy makers. This included internal and external communications, media engagement, the website (uk-cic.org) and social media. This also included the flagship virtual conference for UK-CIC, 'Collaborative Covid Immunology, which the BSI organised, promoted, and delivered.

International Veterinary Vaccinology Network (IVVN)

The BSI published a joint report with the IVVN to review the current state of the veterinary vaccinology landscape and set out the key recommendations to maintain the UK's leading role in this area.

5 Diversify our income

It is essential for the Society's long-term sustainability that we diversify our income through the enhancement of current income generating activities and the creation of new income streams.

In November 2020 the Society launched its first new journal in over sixty years. It has met its initial performance targets and is hoped to grow significantly over the next few years.

The Society increased the number of approaches made to funders resulting in a rise of grants and donations received. This work will continue next year.

The trustees increased the Society's long term sustainability fund to £250k to resource the development of new income sources to ensure the long term sustainability of the Society.

Structure, Governance and Management

Charitable status and administrative details

The Society was registered as a charity in 1966 (Charity number 1043255) and incorporated in England and Wales as a company, limited by guarantee (Company number 03005933). The Society's registered address is Devonshire House, 60 Goswell Road, London EC1M 7AD. It has no share capital and the liability of its members is limited to a sum not exceeding £1. The Society's governing document is the Memorandum and Articles of Association, which was amended on 7 December 2016.

It is also a registered charity in Scotland (Charity number SC047367).

Board of Trustees

The Trustees are company directors for the purposes of the Companies Act and charity Trustees for the purposes of the Charities Act 2011. The current trustees, and any past Trustees who served during the year are listed on page 51.

The Trustees are responsible for directing the Society's activities and for overseeing the management of the affairs of the Society, they delegate the day to day management of the organisation to the chief executive and the senior management team. The Board acts on advice and information from regular meetings with the chief executive and the senior management team.

As part of their induction process, Trustees spend some time at the Society's office, with the chief executive and staff. They are provided a trustee resource pack containing the history of the Society and key information they require to fulfil their duties as Trustee, they are also offered training for new Trustees.

The success of the Society belongs in part to the large number of people who generously volunteer their time to add their experience to our collection of committees, we thank you all.

Finance Sub Committee

The Finance Sub Committee ensures the system of internal control is satisfactory to deliver regulatory compliance, financial probity, value for money, challenge of financial plans, budgets and financial statements, oversight of the annual financial audit, review of investment policy and performance, review of reserves policy, and CEO and staff remuneration.

Nominations Committee

The BSI's Nominations Committee has general oversight concerning the structures and effectiveness of BSI Board of Trustees, committees, advisers and observers. It is also responsible for nominating individuals to represent the views of the BSI on external committees and to identify BSI members to nominate for external awards.

Forum

The Forum represents a diverse mix of immunologists from different career stages, backgrounds and geographic locations, it is responsible for developing policy and advising on communications, education and public engagement work.

Congress Committee

The Congress Committee is responsible for the planning and delivery of the BSI's flagship event, BSI Congress, which takes place two out of every three years. It reviews and approves the scientific programme for Congress.

The Clinical Committee represents the wider clinical immunology and allergy community and aims to enhance communication between scientific and clinical immunology communities.

Group structure

The Society has one wholly owned subsidiary:

BSI Trading Limited is registered in the UK under company registration number 010201739. Its principal activity is to manage the corporate membership, sponsorship, exhibition and other trading activities for the Society. This primarily comprises exhibition and sponsorship for the BSI Congress.

Financial Performance

This year been challenging, however the BSI team worked incredibly hard to deliver a very strong financial performance. Net income climbed to £0.87m from £0.17m last year. Congress was postponed due to COVID-19 restrictions; however, we delivered the BSI's first ever virtual conference. Our journals remain our largest income stream, this was bolstered this year with signing bonuses for our new journal *Immunotherapy Advances* and for the new publishing contract for *Clinical & Experimental Immunology*. The society's diversification of income continued with an increase in grants and donations.

[illegible]

COVID-19 had a significant impact on the society's activities during the year; the postponement of Congress led to a reduction in total costs. Costs in other areas also fell as activities were either postponed or delivered in another form. Travel restrictions also resulted in the withdrawal of our travel grants.

The society spent £161k supporting the UK Coronavirus Immunology Consortium (UK-CIC), a twelve month project to bring together immunology research on COVID-19. This work was funded by a grant from UKRI and NIHR.

The postponement of Congress had an impact on BSI Trading Limited, although the financial success of the virtual conference limited the reduction in income to 57%. The company posted an annual profit of £0.12m (2020: £0.31m). This was gifted to the society.

The society's investment portfolio provided solid income in line with 2020. The value of the portfolio rose by £0.51m producing its best annual performance. On 30 June 2021 investments were valued at £4.45m.

Reserves rose to £4.94m, continuing their rise from £3m five year ago. The BSI also had a year-end cash balance of over £1m for the third consecutive year.

£4.94m Reserves (2020: £4.08m)	£4.5m Investments (2020: £3.9m)	£1.23m Cash (2020: £1.04m)
--	---	--

The central role of immunology in uncovering the impact of COVID-19 on the immune system and into research for treatments and a vaccine puts the BSI in a relatively good position to secure future funding to continue the Society's work supporting the immunology community during this pandemic and beyond.

Investment policy and performance

The Society operates an investment policy to generate capital growth.

The high levels of volatility resulting from the COVID-19 pandemic, continuing UK and global political uncertainty creates a challenging environment in which to manage investments. The Society is a long-term investor and the value of its investments remains significant above its original investment.

Funds are invested with Aberdeen with a long-term objective to generate a capital return of 3% more than inflation over a three year rolling period. Performance was exceptional generating net gains of £0.51m for the year (2020: £0.11m).

The Finance Sub Committee is responsible for reviewing investment performance and policy.

Reserves policy

The BSI operates a risk-based approach to reserves to ensure the BSI holds the most appropriate level of reserves to cover potential risks and to fund invest in new income sources securing the BSI's long term financial health.

The risk register is reviewed annually with monetary values allocated to specific risks, restricted and designated funds. A provision for unknown risks (to give cover for those risks of which the society is not yet aware) is calculated based as a percentage of the risk adjusted fund. The latest review resulted in total required allocated reserves of £2.93m (2020: £2.89m). On 30 June 2021 total reserves were £4.94m, including free reserves (general reserves less fixed assets) of £3.82m giving an excess over the target of £0.89m (2020: £0.86m) available for use by the Society to further its strategic aims. Details of restricted funds can be found in note 17 of the accounts with details of designated funds in note 18.

The calculation of the total required allocated reserves is performed on an annual basis.

Pay policy

Salaries, including Key Management Personnel, are reviewed by the Finance Sub Committee with recommendations for the annual pay rise proposed to the wider Board of Trustees for approval as part of the annual budgeting process. The salary of the Chief Executive is reviewed annually by the Board of Trustees.

Risk management

Good risk management is fundamental to the continued work and sustainability of the Society. We identify and manage risks that could adversely impact the achievement of our strategic purpose and determine the calculated risks we need to take to succeed.

The Society operates a formal framework for the management of risk, taking the view that risk can be positive (opportunity) or negative (threat). The Society operates a risk register incorporating strategic, operational and compliance risks, which are informed by the Society's strategic objectives, performance, voice of our stakeholders, regulatory environment and analysis of the external environment.

The Board delegates day-to-day responsibility for risk management to the Senior Management Team, who are responsible for identifying and evaluating risks to their areas and activities implementing appropriate controls for ongoing mitigation and monitoring.

The Financial Sub Committee reviews the management of risk in detail at each meeting and the Board reviews the Society's strategic and compliance risks twice a year.

The major risks facing the society and the mitigation that we have put in place are as follows:

Risk	Risk response
<p>Failure to diversify our income</p> <p>The Society is heavily reliant on a single source of income: journals.</p>	<p>The Society is looking at opportunities to diversify income including:</p> <ul style="list-style-type: none"> ▪ Working with partners to develop important relationships with funders delivering increased grants and donations ▪ Implementing a fundraising strategy to develop new income streams
<p>Longer-term reduced income from the BSI portfolio of journals</p> <p>The move to open access will impact the income received from the Society's journals.</p> <p>Inflationary price increases may be limited post-pandemic</p>	<p>The Society has</p> <ul style="list-style-type: none"> ▪ Developed a plan with our publisher to limit any financial loss on the move to Open Access ▪ Worked with a publishing consultant to assist with negotiations with our publisher to secure the best financial outcome in new contracts ▪ Launched new journal
<p>Poor handling of government/funding bodies relations</p> <p>Insensitive handling of issues such as vaccines or animal research could leave BSI with poorer reputation</p>	<p>The Society will continue to:</p> <ul style="list-style-type: none"> ▪ Ensure good Forum and President oversight of our statements , sign-off of sensitive letters via President or another trustee. ▪ Ensure SMT discuss all significant Policy and Public Affairs issues
<p>Adverse commentary, publicity or action or poor public perception</p> <p>Public do not know much about the BSI but the risk would be twofold: that we do not talk about issues of importance to members, or that we misrepresent their views</p>	<p>The Society will continue to:</p> <ul style="list-style-type: none"> ▪ All staff, trustees and volunteers who perform media/website/ policy/ public engagement work on behalf of the BSI are properly trained and aware of public's views ▪ CEO oversees and discusses controversial issues with trustees before releasing public statements

Fundraising statement

Although the Society does not actively fundraise from members, occasional donations are received. The Society applies best practice in the tone of its communications and the accuracy of its data to minimise the pressures on supporters. The Society applies best practice to protect supporters' data, never sells or swaps it and ensures that communication preferences can be changed at any time. The Society commits to react to and investigate any complaints received, to learn from them and improve its service. During the year, the Society received no complaints about its fundraising activities.

Future plans

The trustees have approved a new five year strategy commencing July 2021. The new strategy was developed through consultation with staff, trustees, BSI Forum members, Secretaries and editors building on work from the previous six years. The new strategy includes a vision statement:

"Better health for all through immunology"

And an updated mission statement:

"We are committed to supporting our immunology community in driving scientific discovery and to make a positive impact on health"

The strategy is based upon three pillars Connected Community, Careers, Catalysing Change and our underpinning priority: Enablers

Pillar 1: Connected Community

By 2025 we will provide the immunology community the support to establish more connections and to enhance collaboration within the field, with other related scientific disciplines and between sectors. We will do this by:

- Expanding our activities and support to further enable our members to network and engage with each other across the immunology community
- Increasing the number and diversity of interdisciplinary connections with industry as well as between immunology and other relevant research and clinical fields
- Initiating and supporting national and topic specific research consortia efforts relevant to immunology

Pillar 2: Careers

By 2025 we will provide sector leading support to attract and retain talent in immunology. We will do this by:

- Up-skilling and training more of our members than ever before
- Creating a more inclusive and supportive research culture and community, assisting our members and providing opportunities for a career in immunology
- Recognising and promoting outstanding achievements and performance from BSI members

Pillar 3: Catalysing Change

By 2025 we will influence and improve the environment to enable immunology to thrive and deliver positive outcomes for health. We will do this by:

- Having demonstrable impact on public health, policy, practice and research funding issues important to immunology and our members
- Influencing public opinion and engagement in key immunology matters
- Maintaining the BSI as an internationally respected thought leader

Underpinning priority: Enablers

To deliver these ambitious strategic aims we need to maintain the BSI as a sector leading organisation. We will achieve this by:

- Creating a larger and more diverse engaged membership
- Embedding equality, diversity and inclusion in all our activities
- Ensuring the Society's financial sustainability

As part of our strategy the BSI has developed a set of BSI values which underpin all society activities:

We are:

Ambitious and committed
Evidence-based and responsible
Collaborative and inclusive
Agile and energetic

The activities for 2021-22 will focus on:

Pillar 1: Connected Community

- Deliver a successful Congress 2021
- Deliver a new BSI awards ceremony

Pillar 2: Careers

- To successfully increase the careers support the BSI provides to members

Pillar 3: Catalysing Change

- To build the BSI's partnership portfolio and impact
- To continue the BSI's successful programme of vaccine work.

Underpinning priority: Enablers

- Deliver a journals strategy, ensuring optimal financial performance from existing and new journals
- Launch refreshed membership offer
- Develop and launch new CRM system
- Smooth transition to hybrid working

The majority of BSI income is derived from our journals. To date, the submission of papers and journal subscriptions have not been significantly affected by COVID-19.

The Senior Management Team and the Trustees continue to assess the impact of COVID-19 on the Society, together with all other significant risks, in the immediate, medium and longer term. This includes the BSI team's ways of working, our financial requirements, all income streams and the performance of investments.

Trustees' responsibilities

The Trustees (who are also directors of British Society for Immunology for the purposes of company law) are responsible for preparing the Trustees' report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Group and Society and of the income and expenditure of the Group and Society for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable to the United Kingdom and Republic of Ireland; and
- make judgements and estimates that are reasonable and prudent;
- state whether applicable United Kingdom Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume the charity will continue in operation.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Group and Society and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Group and Society and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Each of Trustees confirm that:


- so far as the Trustee is aware, there is no relevant audit information of which the Group and Society's auditor is unaware; and
- the Trustee has taken all steps that he/she ought to have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the Group and Society's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act 2006.

The Trustees are responsible for the maintenance and integrity of corporate and financial information included on the Society's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

Approved by the Trustees and signed on their behalf by:

Arne Akbar
BSI President



Date:

13/10/21

Independent Auditor's Report to the members and trustees of the British Society for Immunology

Opinion

We have audited the financial statements of the British Society for Immunology for the year ended 30 June 2021 which comprise the Group Statement of Financial Activities, the Group and Parent Charitable Company Balance Sheets, the Group Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

give a true and fair view of the state of the group's and the parent charitable company's affairs as at 30 June 2021 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;

have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the trustees' annual report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion:

the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
certain disclosures of trustees' remuneration specified by law are not made; or
we have not received all the information and explanations we require for our audit; or
the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report and from preparing a strategic report.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council

We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.

We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.

We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.

Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.

Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity's trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company's members, as a body, and the charity's trustees, as a body for our audit work, for this report, or for the opinion we have formed.

Moore Kingston Smith LLP

Date 19/10/2021

Neil Finlayson (Senior Statutory Auditor)
for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

Devonshire House
60 Goswell Road
London
EC1M 7AD

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

British Society for Immunology
Consolidated Statement of Financial Activities
Year to 30 June 2021

		Unrestricted funds				
	Note	General funds £'000	Designated funds £'000	Restricted funds £'000	Total 2021 £'000	Total 2020 £'000
Income from:						
Grants and donations	2	2	-	188	190	100
Investments	3	113	-	-	113	112
Charitable activities	4					
Membership		145	-	-	145	170
Partnership work		78	-	-	78	61
Congress		-	-	-	-	464
Meetings and events		105	-	3	108	46
Journals		1,552	-	-	1,552	1,282
Total income		1,995	-	191	2,186	2,235
Expenditure on:						
Raising funds						
Investment management fees		36	-	-	36	33
Cost of raising funds		13	-	-	13	12
Charitable activities						
Membership		156	-	-	156	183
Awards and grants	5	25	-	-	25	136
Congress		166	-	-	166	587
Meetings and events		253	-	-	253	267
Publications and journals		377	-	-	377	358
Policy and Public Affairs		176	-	5	181	190
UK-CIC		-	-	161	161	-
Partnership work		87	-	31	118	-
Education and Careers		62	2	3	67	75
Public engagement		73	-	-	73	86
Communications		146	-	23	169	213
International work		32	-	-	32	36
Total expenditure	6	1,602	2	223	1,827	2,177
Net income (expenditure)						
before gains (losses) on		393	(2)	(32)	359	57
Investments and transfers						
Net gains/(losses) on investments	12	507	-	-	507	110
Transfers between funds		(738)	738	-	-	-
Net income/(deficit)		162	736	(32)	866	167
Reconciliation of funds:						
Funds brought forward		3,771	250	57	4,078	3,911
Funds carried forward		3,933	986	25	4,944	4,078

There are no recognised gains or losses other than those recognised above. All activities are continuing.


The notes on pages 32 to 50 form part of these financial statements

British Society for Immunology
Balance Sheet
30 June 2021

		Group		Charity	
		2021	2020	2021	2020
Fixed assets					
Tangible fixed assets	11	18	13	18	13
Intangible assets	12	37		37	
Investments	13	4,454	3,871	4,454	3,871
		4,509	3,884	4,509	3,884
Current assets					
Debtors	14	130	122	264	418
Cash at bank and in hand		1,227	1,037	1,079	696
		1,357	1,159	1,343	1,114
Liabilities:					
Creditors: amounts falling due within one year	15	(922)	(965)	(908)	(920)
Net current assets		435	194	435	195
Net assets		4,944	4,078	4,944	4,078
Funds:					
Unrestricted funds					
General fund		3,933	3,771	3,933	3,771
Designated fund	18	986	250	986	250
		4,919	4,021	4,919	4,021
Restricted funds	17	25	57	25	57
Total		4,944	4,078	4,944	4,078

These financial statements have been prepared in accordance with the provisions applicable to the small companies regime.

These accounts were approved by the Board and authorised for issue on 13/10/21 and were signed on its behalf by:



Arne Akbar, President

British Society for Immunology, Company Limited by Guarantee
 Company Registration Number 03005933 (England and Wales)

The notes on pages 32 to 50 form part of these financial statements

British Society for Immunology
Consolidated Statement of Cash Flows
30 June 2021

	2021	2020
	£'000	£'000
Cash flows from operating activities:		
<i>Net cash provided by operating activities</i>	203	(118)
Cash flows from investing activities:		
Income from investments	113	112
Purchase of tangible fixed assets	(11)	(11)
Proceeds from the disposal of investments	599	630
Purchase of investments	(595)	(836)
Net cash used in investing activities	105	(105)
Change in cash and cash equivalents in the year	270	33
Cash and cash equivalents at 1 July 2020	1,215	1,182
Cash and cash equivalents at 30 June 2021	1,485	1,215
Net income for the period (as per the statement of financial activities)	866	167
Adjustments for:		
Depreciation charge	9	8
(Gains) on investments	(507)	(110)
Investment income	(113)	(112)
(Increase) decrease in debtors	(8)	49
Increase in creditors	(44)	(120)
Net cash provided by operating activities	203	(118)
Analysis of cash and cash equivalents		
Cash at bank and in hand	1,227	1,037
Cash held by investment managers	258	178
Total cash and cash equivalents	1,485	1,215

The notes on pages 32 to 50 form part of these financial statements

Notes to the financial statements

1 Accounting policies

The principle accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

Basis of preparation

The financial statements are prepared on a going concern basis, under the historical cost convention modified to include the recognition of listed investments measured at fair value, which is consistent with the prior year. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities ("The SORP"), the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and the Charities Act 2011.

The British Society for Immunology ("The Society") meets the definition of a public benefit entity under FRS 102.

General information

The Society is a charitable company incorporated in England and Wales (company number 03005933) and is a charity registered in England and Wales (charity number 1043255) and registered as a charity in Scotland (charity number SC047367). The Society's registered address is Devonshire House 60 Goswell Road, London EC1M 7AD

Critical accounting judgements and key sources of estimation uncertainty

The preparation of financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group and Society accounting policies. In the application of the accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision only affects that period, or in the period of revision and future periods if the revision affected current and future periods.

In the view of the Trustees, no assumptions concerning the future or estimation uncertainty affecting assets or liabilities at the balance sheet date are likely to result in a material adjustment to their carrying amounts in the next financial year.

Going concern

The financial statements are prepared on a going concern basis which assumes the Society and Group will continue to meet its liabilities as they fall due for a period of at least twelve months from the date of the approval of these accounts. The Trustees are monitoring the impact of Covid-19 on the Society and Group. This includes regular review of the pandemic's impact on our members and our ability to deliver our activities a flexible approach to our annual plan, rolling forecasts and in depth review of actual financial results.

The immunology community is at the heart of work on Covid-19 leading to the Society being busier than ever and attracting new funding to support this work. This together with the holding of significant levels of cash and investments result in the Trustees considering the Society and the Group to be a going concern.

Notes to the financial statements

Income

All income is recognised once the Society and Group has entitlement to income, it is probable that income will be received and the amount of income receivable can be measured reliably. Income of the Society is, where applicable, included net of Value Added Tax (VAT) and is allocated to the period to which it relates, carrying forward that part of the income relating to future accounting periods.

Investment income is recognised on a receivables basis and when the amount can be measured reliably.

Expenditure

Liabilities are recognised as soon as there is a legal or constructive obligation committing the Society and Group to that expenditure, it is probable that settlement will be required and the amount of obligation can be measured reliably. Expenditure is recognised on an accruals basis as a liability is incurred, inclusive of VAT, which cannot be recovered.

Expenditure is allocated to a particular activity where the cost relates directly to that activity. The cost of overall direction and administration of each activity, known as "support costs" and comprising the salary and overhead costs of the central function is apportioned based on staff time attributable to Support costs also include governance costs, which comprise organisational administration and compliance with constitutional and statutory requirements. The allocation of support and governance costs is analysed in notes 7 and 8.

Employee benefits

Short-term benefits including holiday pay are recognised as an expense in the period in which the service is received.

Termination payments are accounted for on an accruals basis and in line with FRS 102.

The Society contributes to a Group pension scheme, the assets of which are administered by Royal London Plc. They are defined contribution schemes. All contributed costs are accounted for on the basis of charging the cost of providing pensions over the period when the Society and Group benefits from the employees' service. The Society and Group has no further liability under the scheme.

Leasing and hire purchase commitments

Rentals paid under operating leases are charged to the income and expenditure account on a straight line basis over the lease term. The Society holds no assets under finance leases or hire purchase contracts.

Tangible fixed assets

Tangible assets are stated at cost less accumulated depreciation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Depreciated is provided at 33% in order to write off each asset over its estimated useful life.

Intangible fixed assets

Intangible assets are stated at cost less accumulated amortisation. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. The minimum threshold is £1,000. Amortisation is provided at 20% in order to write off each asset over its estimated useful life. Assets in the course of construction are not amortised.

Notes to the financial statements

Investments

Investments are a form of basic financial instrument and are initially shown in the financial statements at fair value. Movements in the fair value of investments are shown as net gains and losses in the Statement of Financial Activities.

Profits and losses on the realisation of investments are shown as realised gains and losses in the Statement of Financial Activities. Net gains and losses on investments are calculated between sales proceeds and their opening carrying values or their purchase price if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

The investment in the subsidiary undertaking is included at cost with provision being made for any permanent diminution in value.

Financial instruments

I) Financial assets

Basic financial assets, including trade and other receivables, cash and bank balances, are initially recognised at transaction value and subsequently measured at amortised cost. Other financial assets, including investments, are initially measured at fair value. Financial assets are derecognised when:

- a) the contractual rights to the cash flows of the asset expire or are settled, or
- b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or
- c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Cash at bank and cash in hand includes cash and short-term highly liquid investments with a short maturity of three months or less.

II) Financial liabilities

Basic financial liabilities, including trade and other payables, are initially recognised at transaction price. Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Financial liabilities held at amortised cost comprise all creditors except social security and other taxes and provisions.

Provisions

Provisions are recognised where the Society has a present legal or constructive obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Provisions are measured at the present value or the expenditures expected to be required to settle the obligation.

Notes to the financial statements

Fund accounting

Unrestricted funds are those funds available to the Society and Group for general purposes. They include funds designated by the Trustees for particular purposes where their use remains at the discretion of the Trustees. It is the policy of the Trustees to retain in unrestricted funds, amounts which in their judgement, can help to mitigate the short-term effects of income volatility; and retain as long-term investment funds to generate sufficient income to meet current and future operational activities of the Society.

Restricted funds are those funds available to the Society and Group restricted to a specific purpose or are subject to particular donor imposed conditions. Further information is available in the reserves section of the Trustees' report.

Notes to the financial statements

2 Income from grants and donations

	Unrestricted funds £'000	Restricted funds £'000	2021 Total funds £'000	2020 Total funds £'000
Grants	-	149	149	-
Donations	2	39	41	100
Total	2	188	190	100

3 Income from investments and interest

	Unrestricted £'000	Restricted £'000	2021 Total £'000	2020 Total £'000
Listed investments				
Investment Income	113	-	113	109
Bank deposit interest	-	-	-	3
Total	113	-	113	112

4 Income from charitable activities

	Unrestricted funds £'000	Restricted funds £'000	2021 Total funds £'000	2020 Total funds £'000
Member subscriptions	145	-	145	170
Corporates and partnership income	78	-	78	61
Congress	-	-	-	464
Meetings and events	105	3	108	45
Journals	1,552	-	1,552	1,282
Total	1,880	3	1,883	2,022

Notes to the financial statements

5 Awards and grants

	2021	2020
	Total	Total
	funds	funds
	£'000	£'000
Awards and grants to individuals	5	104
Other Awards and Grants	-	-
Support costs (note 7)	20	32
Total	25	136

Awards and grants were paid to a total of 36 (2020– 248) individuals.

6 Total expenditure

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2021 Total £'000
<i>Raising funds</i>				
Investment management fees	36	-	-	36
Fundraising	13	-	-	13
<i>Charitable Expenditure:</i>				
Membership	156	-	-	156
Awards and grants	25	-	-	25
Congress	166	-	-	166
Other meetings and events	253	-	-	253
Publications and journals	377	-	-	377
Policy and Public Affairs	176	-	5	181
UK-CIC	-	-	161	161
Partnership work	87	-	31	118
Education and Careers	62	2	3	67
Public engagement	73	-	-	73
Communications	146	-	23	169
International Work	32	-	-	32
Total	1,602	2	223	1,827

Allocation of support costs to charitable activities:

	Direct costs £'000	Support costs £'000	2021 Total £'000
<i>Raising funds</i>			
Investment management fees	36	-	36
Cost of raising funds	13	-	13
<i>Charitable activities</i>			
Membership	91	65	156
Awards and grants	5	20	25
Congress	140	25	166
Other meetings and events	211	42	253
Publications and journals	313	64	377
Policy and Public Affairs	118	63	181
UK-CIC	161	-	161
Partnership work	110	8	118
Education and Careers	47	20	67
Public engagement	52	21	73
Communications	91	78	169
International Work	32	-	32
Total	1,421	406	1,827

Notes to the financial statements

6 Total expenditure (continued)

Support costs are as follows:

	2021 £'000	2020 £'000
Staff costs	185	254
Premises costs	71	91
Depreciation	9	8
IT and electronic communications costs	65	60
Other	50	105
Recruitment fees	9	10
Governance costs (note 7)	12	11
Total	401	538

Support costs have been allocated based on time spent by departments supporting the various activities.

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2020 £'000
<i>Raising funds</i>				
Investment management fees	33	-	-	33
Fundraising	12	-	-	12
<i>Charitable Expenditure:</i>				
Membership	183	-	-	183
Awards and grants	136	-	-	136
Congress	587	-	-	587
Other meetings and events	267	-	-	267
Publications and journals	358	-	-	358
Policy and public affairs	173	-	18	191
Education and careers	75	-	-	75
Public engagement	63	-	23	86
Communications	183	-	30	213
International work	36	-	-	36
Total	2,106	-	71	2,177

Notes to the financial statements

7 Governance costs

	2021	2020
	£'000	£'000
Auditor's remuneration - audit	11	10
Auditor's remuneration - other	1	1
Total	12	11

8 Net income before gains (losses) on investments

This is stated after charging:	2021	2020
	£'000	£'000
Staff costs (note 9)	1,103	905
Operating lease rental	70	90
Depreciation	9	8
Auditor's remuneration - audit	11	10
Auditor's remuneration - other	1	1

Notes to the financial statements

9 Staff costs

Staff costs during the year were as follows:

	2021 £'000	2020 £'000
Wages and salaries	962	781
Social security costs	97	84
Pension costs	44	41
Total	1,103	905

The average monthly number of employees during the year was as follows:

	2021	2020
Direct charitable activities	17	14
Administration of the charity	3	4
	20	18

Number of employees whose annualised emoluments fall within following ranges for the year:

	2021	2020
£60,001 - £70,000	2	-
£70,001 - £80,000	1	1
£120,001 - £130,000	-	1
£130,001 - £140,000	1	-

Pension contributions for these employees were £19,625 (2020 - £9,481).

The number of staff for whom retirement benefits are accruing under money purchase pension schemes amounted to 21 (2020 - 16).

The Society considers its key management personnel comprise the Trustees and the Senior Management Team (SMT). The Trustees provide their time free of charge. The total remuneration, employer's national insurance contributions, benefits and pensions paid to the SMT was £484,192 (2020 - £436,269).

The relevant staff costs have been included in the costs of charitable activities. The gender split in the society workforce is 74% female 26% male (2020: 74% female 26% male). All roles are evaluated and paid in accordance with external benchmarking irrespective of gender.

10 Trustees' remuneration

No trustee received any remuneration for his or her services during the year (2020 - none). During the year expenses totalling £nil (2020 - £7,984) were reimbursed to nil trustees (2020 - 10).

One trustee received a prize of £25 for best presentation as voted by attendees of a regional meeting (2020 - none).

Notes to the financial statements

11 Tangible assets of the Group and charity

	Computer equipment £'000	Office equipment and furniture £'000	Office refurbishment and improvement £'000	Total £'000
Cost or valuation				
At 1 July 2020	72	6	22	100
Additions	11	-	-	11
Disposals	(54)	(6)	(22)	(82)
At 30 June 2021	29	-	-	29
Depreciation				
At 1 July 2020	59	6	22	87
Charge for the year	9	-	-	9
Eliminated on disposal	(57)	(6)	(22)	(85)
At 30 June 2021	11	-	-	11
Net book value				
At 30 June 2021	18	-	-	18
At 1 July 2020	13	-	-	13

12 Intangible assets of the Group and charity

	IT software £'000	Total £'000
Cost or valuation		
At 1 July 2020	-	-
Additions	37	37
Disposals	-	-
At 30 June 2021	37	37
Depreciation		
At 1 July 2020	-	-
Charge for the year	-	-
Eliminated on disposal	-	-
At 30 June 2021	-	-
Net book value		
At 30 June 2021	37	37
At 1 July 2020	-	-

Construction of a new CRM system started in the year and is expected to be completed next year.

Notes to the financial statements

13 Investments

	Group		Charity	
	2021	2020	2021	2020
	£'000	£'000	£'000	£'000
Market value at 1 July 2020	3,693	3,632	3,693	3,632
Disposals proceeds	(599)	(673)	(599)	(673)
Realised losses	46	(21)	46	(21)
Additions at cost	595	622	595	622
Unrealised gains	461	131	461	131
Market value at 30 June 2021	4,196	3,692	4,197	3,693
Cash held with investment managers	258	178	258	178
Total investments	4,454	3,871	4,454	3,871

Total Group investments includes £100 investment in subsidiary

	Group		Charity	
	2021	2020	2021	2020
	£'000	£'000	£'000	£'000
At 30 June 2021 the listed investments comprised the following:				
UK equities	1,157	1,510	1,157	1,510
Overseas equities	1,944	1,643	1,944	1,643
Investment instruments	1,353	718	1,353	718
Total	4,454	3,871	4,454	3,871
Historical cost of listed investments	3,470	3,268	3,470	3,268

At 30 June 2021 the holding in ASC (Offshore) Sterling Fixed Interest Fund Z Inc. represents 5.06% of the total market value of the portfolio of listed investments.

Notes to the financial statements

13 Investments (continued)

Investment in subsidiary undertaking

The Society owns 100% of the ordinary issued share capital of BSI Trading Limited, a company registered in England and Wales (Company number 01021739). Its registered address is Devonshire House, 60 Goswell Road, London EC1M 7AD. The principal activity of the company is the management of corporate membership, sponsorship, exhibition and other trading activities for the Society.

A summary of the results of the subsidiary is shown below:

	2021 £'000	2020 £'000
Turnover	133	307
Operating costs	-	-
Operating profit	133	307
Administration costs	(10)	(14)
Profit(loss) for the financial period	123	293
Distribution to parent charity	(123)	(293)
Retained in subsidiary	-	-

The company's assets and liabilities at 30 June 2021 were as follows:

Assets	148	233
Liabilities	(147)	(233)
Net assets	-	-

14 Debtors

	Group		Charity	
	2021 £'000	2020 £'000	2021 £'000	2020 £'000
Trade debtors	14	15	14	1
Other debtors	-	1	-	1
Prepayments and accrued income	92	106	92	106
Amount owed by subsidiary undertaking	-	-	134	310
VAT receivable	24	-	24	-
Total	130	122	264	418

Notes to the financial statements

15 Creditors

	Group		Charity	
	2021	2020	2021	2020
	£'000	£'000	£'000	£'000
Trade creditors	60	40	60	33
Other taxes and social security costs	49	39	49	39
VAT payable	-	40	-	40
Other creditors	13	18	13	18
Accruals and deferred income	800	829	786	790
Total	922	965	908	920

Included within the above is deferred income as set out below:

	Group	Charity
	2021	2021
	£'000	£'000
Deferred income brought forward at 1 July	919	919
Additional income deferred during the year	800	800
Brought forward funds released in the year	(919)	(919)
Deferred income carried forward at 30 June	800	786

Deferred income comprises advance payments of journal royalties and memberships fees.

16 Operating leases

The total future minimum lease payments under non cancellable operating leases is as follows:

	Land and Buildings	
	2021	2020
	£'000	£'000
Payments which fall due:		
Within one year	-	47
Between one and two years	-	-

Notes to the financial statements

17 Restricted funds

	At 1 July 2020	Income	Expenditure	At 30 June 2021
Meeting funds	34	-	-	34
Celebrate vaccines	10	-	(10)	-
Covid-19	13	-	(13)	-
Connect on coronavirus	-	5	(5)	-
Autoimmunity	-	15	(5)	10
UK-CIC	-	137	(161)	(24)
Vaccine taskforce	-	26	(26)	-
BiteSized immunology	-	8	(3)	5
Total	57	191	(223)	25

Meeting funds

Donations to the Society by individuals to promote certain immunological issues.

Celebrate Vaccines

The New Venture Fund grant provided to enhance the success of the Gavi 2020 replenishment, though the BSI's Celebrate Vaccines campaign.

Covid-19

A grant from the Lorna and Yuti Chernajovsky Biomedical Research Foundation for BSI's work on Covid-19.

Connect on Coronavirus

A donation to fund the Society's series of webinars providing information which may contribute to the understanding and treatment of COVID-19.

Autoimmunity

A grant from the Lorna and Yuti Chernajovsky Biomedical Research Foundation for administrative support for the development and management of the autoimmune research initiative.

UK-CIC

A grant for the BSI support provided to the UK Coronavirus Immunology Consortium (UK-CIC). Invoices are raised quarterly for expenses incurred, the final invoice for reimbursement of the remaining costs will be raised after the year end.

Vaccine taskforce

A grant from the European Federation of Immunological Societies (EFIS) for the EFIS Vaccine Taskforce work led by the BSI.

BiteSized Immunology

Donations received to update the BSI's online resource, BiteSized Immunology, which provides a comprehensive guide to the immune system especially suitable for biomedical undergraduates and those new to immunology.

Notes to the financial statements

17 Restricted funds (Continued)

	At 1 July 2019 £'000	Income £'000	Expenditure £'000	At 30 June 2020 £'000
Meeting funds	34	-	-	34
Celebrate vaccines	-	74	(64)	10
Covid-19	-	20	(7)	13
Total	34	94	(71)	57

18 Designated funds

	At 1 July 2020	Designated in year	Utilised / released	At 30 June 2021
Long term sustainability	150	100	(2)	248
Office refurbishment	100	-	(100)	-
CRM project	-	150	(37)	113
Career development programme	-	625	-	625
Total	250	875	(139)	986

Long term sustainability

The long term sustainability fund provides resources for investing in the financial sustainability of the charity over the next five years.

Office refurbishment

Funds designated for office refurbishment were released when the office lease was not renewed

CRM project

The CRM project fund provides resources to develop and implement a new CRM system together with an upgrade to the BSI website

Career development programme

The Career development programme will fund a significant expansion in the careers support the BSI offers to our members. This includes two main streams: our career-enabling activities and our career-enhancing activities.

Notes to the financial statements

19 Analysis of nets assets between funds

Group				2021
	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	Total funds £'000
Tangible fixed assets	18	-	-	18
Intangible assets	37	-	-	37
Investments	4,454	-	-	4,454
Current assets	346	986	25	1,357
Current liabilities	(922)	-	-	(922)
Total Funds	3,933	986	25	4,944

Charity				2021
	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	Total funds £'000
Tangible fixed assets	18	-	-	18
Intangible assets	37	-	-	37
Investments	4,454	-	-	4,454
Current assets	332	986	25	1,343
Current liabilities	(908)	-	-	(908)
Total Funds	3,933	986	25	4,944

The total unrealised gains (losses) as at 30 June 2021 constitutes movements on revaluation and are as follows:

	2021 £'000	2020 £'000
Unrealised gains (losses) included above:		
On investments	983	391
Total unrealised gains (losses) at 30 June	983	391
Reconciliation of movements in unrealised gains (losses)		
Unrealised gains at 1 July	522	391
Less: in respect to disposals in the year	-	-
	522	391
Add: net gains (losses) arising on revaluation arising in the year	461	131
Total unrealised gains (losses) at 30 June	983	522

Notes to the financial statements

19 Analysis of nets assets between funds (Continued)

Group	£'000	£'000	£'000	2020 £'000
Tangible fixed assets	13	-	-	13
Investments	3,871	-	-	3,871
Current assets	852	250	57	1,159
Current liabilities	(965)	-	-	(965)
Total Funds	3,771	250	57	4,078

	Unrestricted funds £'000	Designated funds £'000	Restricted funds £'000	2020 Total funds £'000
Charity				
Tangible fixed assets	13	-	-	13
Current assets	3,871	250	57	4,178
Current liabilities	807	-	-	807
Current liabilities	(920)	-	-	(920)
Total Funds	3,771	250	57	4,078

20 Share capital

The company is limited by guarantee and therefore has no share capital. Each member's liability is limited to £1.

21 Related party transactions

An oral prize of £25 was made to Emma Chambers at a London Immunology Group meeting.
Calum Bain is a member of the Editorial Board of *Immunology*, no payments were made in relation to this.

There were no other related party transactions that required disclosure in the current financial period (2020: none).

Notes to the financial statements

22 Comparative consolidated statement of financial activities

	Unrestricted funds			2020 £'000
	General £'000	Designated £'000	Restricted £'000	
Income from:				
Donations	6	-	94	100
Investments	112	-	-	112
Charitable activities				
Membership	170	-	-	170
Partnership work	61	-	-	61
Congress	464	-	-	464
Meetings and events	45	-	-	45
Journals	1,282	-	-	1,282
Total income	2,140	-	94	2,234
Raising funds				
Investment Management Fees	33	-	-	33
Cost of raising funds	12	-	-	12
Charitable activities				
Membership	183	-	-	183
Awards and grants	136	-	-	136
Congress	587	-	-	587
Meetings and events	267	-	-	267
Publications and journals	358	-	-	358
Policy and Public Affairs	173	-	18	191
Education and Careers	75	2,000	-	77
Public engagement	63	-	23	86
Communications	183	-	30	213
International work	36	-	-	36
Total expenditure	2,106	2	71	2,179
Net income before gains (losses) on investments	34	(2)	23	55
Net gains/(losses) on investments	110	-	-	110
Transfers between funds	(144)	144	-	-
Net income	0	142	23	165
Reconciliation of funds:				
Funds brought forward	3,771	106	34	3,911
Funds carried forward	3,771	248	57	4,076

Notes to the financial statements

23 Charity statement of financial activities

	Unrestricted funds			Total	Total
	General funds	Designated funds	Restricted funds	2021	2020
	£'000	£'000	£'000	£'000	£'000
Income from:					
Grants and donations	2	-	188	190	100
Investments	113	-	-	113	112
Charitable activities					
Membership	145	-	-	145	170
Partnership work	10	-	-	10	-
Congress	-	-	-	-	208
Meetings and events	41	-	3	44	57
Journals	1,552	-	-	1,552	1,282
Gift Aid and recharge from BSI	132	-	-	132	305
Trading Limited					
Total income	1,995	-	191	2,186	2,234
Expenditure on:					
Raising funds					
Investment management fees	36	-	-	36	33
Cost of raising funds	13	-	-	13	12
Charitable activities					
Membership	156	-	-	156	183
Awards and grants	25	-	-	25	136
Congress	166	-	-	166	587
Meetings and events	253	-	-	253	267
Publications and journals	377	-	-	377	358
Policy and Public Affairs	176	-	5	181	190
UK-CIC	-	-	161	161	-
Partnership work	87	-	31	118	-
Education and Careers	62	2	3	67	75
Public engagement	73	-	-	73	86
Communications	146	-	23	169	213
International work	32	-	-	32	36
Total expenditure	1,602	2	223	1,827	2,177
Net income (expenditure) before gains (losses) on investments and transfers	393	(2)	(32)	359	57
Net gains/(losses) on investments	507	-	-	507	110
Transfers between funds	(738)	738	-	-	-
Net income/(deficit)	162	736	(32)	866	167
Reconciliation of funds:					
Funds brought forward	3,771	250	57	4,078	3,911
Funds carried forward	3,933	986	25	4,944	4,078

Board of Trustees

Position	Current office holder	Date of appointment / resignation	2020-21 Board attendance	2019-20 committees	2020-21 Committee attendance
President	Professor Arne Akbar	Appointed December 2018	5/5	Forum, Nominations & Congress Committees	4/4 1/1 2/4
Treasurer	Dr Fiona Culley	Appointed July 2017	5/5	Finance Sub Committee & Congress Committee	5/5 4/4
Chair of Forum	Professor Ann Ager	Appointed December 2018	5/5	Forum & Nominations Committee	4/4 1/1
Clinical Secretary	Professor Colin Dayan	Appointed October 2019	5/5	Forum, Clinical & Congress Committees	3/4 2/4
Early Career Trustee	Dr Calum Bain	Appointed July 2018	5/5		
Early Career Trustee	Dr Emma Chambers	Appointed December 2018	5/5		
Co-opted Trustee	Robert Davies	Appointed October 2016	5/5	Nominations Committee	1/1
Trustee	Professor Deborah Dunn-Walters	Appointed July 2019	3/5		
Trustee	Professor Matthias Eberl	Appointed January 2017	5/5	Nominations Committee	1/1
Co-opted Trustee	Dr Paul Harding	Re-appointed July 2019	5/5	Finance Sub Committee	5/5
Co-opted Trustee	Dr Edith Hessel	Appointed January 2017	5/5		
Co-opted Trustee	James Lowe	Appointed July 2019	4/5	Finance Sub Committee	5/5
Trustee	Professor Allan Mowat	Re-appointed May 2019	5/5		
Trustee	Dr Divya Shah	Appointed December 2018	5/5	Nominations Committee	1/1

Key management personnel

Name	Position
Dr Doug Brown	Chief Executive
Otto Balsiger	Finance Director
Dr Jennie Evans	Director of External Affairs
Jane Sessenwein	Head of Events & Conferences
Lucy McIver	Head of Publishing

Principal professional advisers

Name	Position
Bankers	Bank of Scotland 14/16 Cockspur Street London EC2V 6DL
External auditors	Moore Kingston Smith LLP Devonshire House 60 Goswell Road London EC1M 7AD
Investment advisers	Aberdeen Standard Capital 14th Floor 30 St Mary Axe London EC3A 8BF
Solicitors	Russell Cooke LLP 2 Putney Hill London SW15 6AB

Committees

Nominations Committee

Name	Position
Professor Arne Akbar	Chair, BSI President
Professor Ann Ager	Forum Chair and Trustee
Robert Davies	BSI Co-opted Trustee
Professor Matthias Eberl	Trustee
Dr Divya Shah	Trustee
Dr Doug Brown	BSI CEO (observer)

Finance Sub Committee

Name	Position
Dr Fiona Culley	BSI Treasurer
James Lowe	Co-opted Trustee
Paul Harding	Co-opted Trustee
Dr Doug Brown	BSI Chief executive

Forum

Name	Position
Professor Ann Ager	Chair
Professor Arne Akbar	BSI Preseident
Dr Colin Dayan	Clinical Secretary
Dr Donald Palmer	Education & Careers Secretary
Professor Donald Davidson	Public Engagement Secretary
Dr Doug Brown	BSI Chief Executive
Dr Megan Macleod	Regional Representative - Scotland
Dr Helen McGettrick	Regional Representative - England
Dr Karim Dib	Regional Representative - Northern Ireland
Dr Simone Cuff	Regional Representative - Wales
Dr Louise Topping	Early Career Representative
Dr Alice Burton	Early Career Representative
Dr Faith Uwadiae	Early Career Representative
Dr Edoardo Prediletto	Early Career Representative
Dr Lauren Campbell	PhD Representative
Dr Niamh Richmond	PhD Representative
Dr Federica Villanova	Industry Representative
Dr Matthew Buckland	Clinical Representative
Dr Tomaz Garcez	Clinical Representative
Dr Elma Tchilian	Veterinary Representative

Committees

Congress Committee

Name	Position
Professor Gary Entrican	BSI Congress Secretary
Professor Arne Akbar	BSI President
Dr Fiona Culley	BSI Treasurer
Dr Colin Dayan	BSI Clinical Secretary
Professor Mark Coles	BSI Congress Secretary Elect
Professor Linda Wooldridge	Member
Professor James Brewer	Member
Dr Martina Colicchia	Early Career Representative
Dr Alexandra Spencer	Member
Dr Deena Gibbons	Member
Dr John Tregoning	Member
Dr Sinisa Savic	Clinical member
Dr Margarita Dominguez	Member
Dr James Harker	Member
Dr Graham Cook	Member
Dr Sandra Sacre	Member

Clinical Committee

Name	Position
Dr Adrian Heaps	Association for Clinical Biochemistry
Dr Richard Herriot	Association of Clinical Pathologists
Dr Chris Scott	Institute of Biomedical Science
Dr Tariq El-Shanawany	British Society for Allergy & Clinical Immunology
Dr Stephen Hughes	British Paediatric Allergy Immunology & Infections Group
Dr Siraj Misbah	Special Advisory Committee on Immunology (RCPATH SAC)
Dorothea Grosse-Kreul	Immunology & Allergy Nurses group
Dr Kavitha Sooriyakumar	Trainee Rep
Dr Shuaib Nasser	Joint Committee on Immunology & Allergy (JCIA)
Dr Sinisa Savic	UK Primary Immunodeficiency Network (UKPIN)
Dr Colin Dayan	Chair/Clinical Secretary
Dr Doug Brown	BSI Chief Executive

Journals

Immunology - Editorial Team

Name	Position
Professor Simon Milling	Editor-in-Chief
Dr Awen Gallimore	Associate Editor
Dr Florent Ginhoux	Associate Editor
Professor Kathleen McCoy	Associate Editor
Professor Francisco J. Quintana	Associate Editor
Dr Meera Ramanujam	Associate Editor

Clinical and Experimental Immunology - Editorial Team

Name	Position
Professor Leonie Taams	Editor-in-Chief
Professor Angelo Manfredi	Section Editor - autoimmunity
Professor Tanja de Gruij	Section Editor - cancer immunity
Professor Ciriaco Piccirillo	Section Editor - immune-mediated inflammatory diseases
Dr Cindy Ma	Section Editor - immunodeficiency
Dr daniel Douek	Section Editor - infectious diseases and vaccines
Professor Xiao-Ning Xu	Section Editor - infectious diseases and vaccines
Professor Sandra Amor	Section Editor - neuroimmunology

Immunotherapy Advances - Editorial Team

Name	Position
Professor Tim Elliot	Editor-in-Chief
Professor Stefan Barth	Regional Editor: Africa
Associate Professor Marianne Boes	Regional Editor: Europe
Professor Adrianna Bonomo	Regional Editor: South America
Professor Tao Dong	Regional Editor: Asia
Dr Stephanie K Dougan	Regional Editor: North America
Associate Professor Menno van Zelm	Regional Editor: Australasia

Regional and Affinity groups

Affinity Groups

Group	Position	
Autoimmunity Affinity Group	Chair	Professor Lucy Walker
	Secretary	Dr Kathryn Steel
	Treasurer	Dr James Pearson
Comparative Veterinary Immunology Group	Resigned 2019	Dr Elma Tchilian
	Secretary	Dr Lindert Benedictus
	Treasurer	Dr Kate Sutton
Histocompatibility & Immunogenetics Group	Chair	Professor David Briggs
	Secretary	Dr Luke Foster
Immunometabolism Affinity Group	Co-Chair	Dr Laura Pallett
	Co-Chair	Dr Linda Sinclair
	Secretary	Dr Sarah Dimeloe
	Treasurer	Dr Anna Schurich
Immunosenescence Affinity Group	Chair	Dr Sian Henson
	Secretary	Dr Natalie Riddell
	Treasurer	Dr Catarina Henriques
Infection and Immunity Group		
Inflammation Affinity Group	Chair	Professor Peter Barlow
	Treasurer	Dr Joanne Konkel
	Communications	Dr Jack Rivers-Auty
Leukocyte Migration Group	Chair	Dr Myriam Chimen
	Secretary/Treasurer	Dr Graeme O'Boyle
Mathematical Modelling Group	Chair	Professor Carmen-Molina Paris
	Secretary	Professor Mark Coles
	Treasurer	Professor Grant Lythe
Neuroimmunology Group	Chair	Professor Sandra Amor
	Secretary	Dr Sarosh Irani
Vaccine Affinity Group	Chair	Dr Phil Hogarth
	Secretary	Dr Julia Tree
	Treasurer	Dr Bernardo Villarreal-Ramos
Tumour Immunology Affinity Group	Chair	Professor Benjamin Willcox
	Secretary	Dr Seth B. Coffelt
	Treasurer	Professor Awen Gallimore

Regional and Affinity groups

Regional Groups

Group	Position	
Aberdeen Immunology Group	Chair	Dr Isabel Crane
	Treasurer	Dr Soumya Palliyil
Bristol Immunology Group	Chair	Dr Laura Rivino
	Secretary	Dr Dronwen Burton
	Treasurer	Dr Lindsay Nicholson
Cambridge Immunology Group	Chair	Dr Brian Ferguson
	Secretary/Treasurer	Dr Louise Boyle
East Anglia Immunology Group	Secretary	Dr Maria O'Connell
	Treasurer	Dr Cristina Fanutti
Edinburgh Immunology Group	Co-Chair	De Cecile Benezech
	Co-Chair	Dr Laura McCulloch
	Secretary	Dr Matthew Burgess
	Secretary	Dr Tovah Shaw
	Treasurer	Dr David Donaldson
Greater Manchester Immunology Group	Chair	Professor Richard Grecis
	Secretary	Dr Ana Villegas-Mendez
	Treasurer	Dr Joanne Konkel
Immunology North East	Chair	Dr Kevin Marchbank
	Secretary	Dr Antony Antoniou
	Treasurer	Dr Andy Knight
London Immunology Group	Chair	Dr James Harker
	Secretary	Dr Laura Pallett
	Treasurer	Dr Alice Burton
Merseyside Immunology Group	Secretary	Dr Qibo Zhang
	Treasurer	Dr Steve Christmas
Oxford Immunology Group	Chair	Dr Alexandra Spencer
	Co-Secretary	Dr Louise Johnson
	Co-Secretary	Dr Anita Milicic
	Treasurer	Dr Philipp Kruger

Regional and Affinity groups

Regional Groups

Group	Position	
South Wales Immunology Group	Chair	Dr You Zhou
	Secretary	Dr Rebecca Aicheler
	Treasurer	Dr Ceri Fielding
Tayside Immunology Group	Chair	Professor Simon Arthur
	Secretary	Dr Mahima Swamy
	Treasurer	Dr Stephen Matthews
Ulster Immunology Group	President	Dr Yvonne Dombrowski
	Secretary	Dr Karim Dib
Wessex Immunology Group	Chair	Dr Emma Reeves
	Secretary	Dr Alison Hill
	Treasurer	Dr Diogo Silva
West Midlands Immunology Group	Co-Chair	Dr David Bending
	Co-Chair	Dr Kendle Maslowski
	Secretary	Dr Lia Liaskou
	Treasurer	Dr Zhi Li
West of Scotland Immunology Group	Chair	Dr Megan MacLeod
	Secretary	Dr Ed Roberts
	Treasurer	Dr Hannah Scales
Yorkshire Immunology Group	Chair	Dr Gina Doody
	Secretary	Dr Erica Wilson